Arrowhead Pharmaceuticals Inc
$ 63.39
2.88%
26 Feb - close price
- Market Cap 8,876,640,000 USD
- Current Price $ 63.39
- High / Low $ 63.71 / 60.88
- Stock P/E 38.42
- Book Value 4.14
- EPS 1.65
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.14 %
- ROE 0.76 %
- 52 Week High 76.76
- 52 Week Low 9.57
About
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
Analyst Target Price
$81.36
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-10 | 2025-11-25 | 2025-08-07 | 2025-05-07 | 2025-02-04 | 2024-11-27 | 2024-08-08 | 2024-05-09 | 2024-02-06 | 2023-11-29 | 2023-08-07 | 2023-05-02 |
| Reported EPS | 0.22 | -0.11 | -1.26 | 2.75 | -1.39 | -1.37 | -1.38 | -1.02 | -1.24 | -1.02 | -0.96 | 0.45 |
| Estimated EPS | 0.1149 | -0.3099 | -0.86 | -0.4622 | -0.7234 | -0.922 | -0.55 | -0.16 | -0.82 | -0.6 | -0.65 | -0.64 |
| Surprise | 0.1051 | 0.1999 | -0.4 | 3.2122 | -0.6666 | -0.448 | -0.83 | -0.86 | -0.42 | -0.42 | -0.31 | 1.09 |
| Surprise Percentage | 91.4708% | 64.5047% | -46.5116% | 694.9805% | -92.1482% | -48.59% | -150.9091% | -537.5% | -51.2195% | -70% | -47.6923% | 170.3125% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARWR
2026-02-24 14:53:06
Arrowhead Pharmaceuticals, Inc. announced its participation in several upcoming investor events in March 2026, including the TD Cowen 46th Annual Health Care Conference, Leerink 2026 Global Healthcare Conference, 2026 Jefferies Biotech on the Beach Summit, and Barclays 28th Annual Global Healthcare Conference. These events will involve fireside chats, investor group dinners, and one-on-one meetings. The company is known for developing medicines that treat intractable diseases by silencing specific genes using RNA interference.
2026-02-24 10:53:06
Arrowhead Pharmaceuticals, Inc. has achieved a 201.24% return over the past year, significantly outperforming the S&P 500 and establishing itself as a multibagger in the biotechnology sector. The company reported strong financial results including nearly 3% growth in net sales, $21.84 million in operating cash flow, and $195.2 million in net profit. High institutional holdings of 96.34% reflect strong investor confidence in its market position and financial performance.
2026-02-23 07:08:00
The article discusses Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), highlighting a positive near-term sentiment while noting a mid-term weak bias within a long-term strength context. It details a significant 72.7:1 risk-reward setup targeting a 20.7% gain with minimal risk, and presents three AI-generated trading strategies. The analysis indicates current support testing and anticipates resistance if the support holds.
2026-02-21 12:41:47
Arrowhead Pharmaceuticals is intensifying its competition with Ionis as it focuses on its drug plozasiran, which targets APOC3 for hypertriglyceridemia. Plozasiran is expected to reach the market around 2025, following Ionis's olezarsen. This development highlights a two-company race in the treatment of high triglycerides.
2026-02-21 11:38:04
King Luther Capital Management Corp significantly increased its stake in Arrowhead Pharmaceuticals (ARWR) by 54.7% in Q3, bringing its total ownership to 80,640 shares. This move aligns with a "Moderate Buy" consensus from analysts, who have also raised their price targets for ARWR. Despite institutional buying, company insiders have recently been net sellers, disposing of over half a million shares.
2026-02-20 09:01:08
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is highlighted as a high-growth company with a promising technical breakout opportunity. The biopharmaceutical firm boasts exceptional revenue and earnings growth, supported by a strong RNAi platform and strategic partnerships. After a significant rise, the stock is currently in a consolidation phase near a key resistance point, suggesting a potential restart of its upward trend.
